At a glance
- Originator SSP Co
- Class Antibacterials; Quinolones; Small molecules
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 04 Aug 1998 Discontinued-Preclinical for Bacterial infections in Japan (Unknown route)
- 22 Jan 1996 Preclinical development for Bacterial infections in Japan (Unknown route)